NICE are proposing taking the majority of the old style injectables off the table for new patients on the grounds that they are not cost effective. So it’s OK if you’re already on one, but the newly diagnosed would not have the options of Avonex, Plegridy, Betaferon, Rebif Or Copaxone available to them. The only one considered to be ‘cost effective’ is Extavia.
It’s bizarre, because many newly diagnosed are not being given a choice, but are just put on (typically) Copaxone. And we are constantly telling people they should have a choice, and that other DMDs are more effective, eg Tecfidera.
And yet Copaxone to me has one of the least, average side effects of any of the DMDs. I know we are all different, and other people have had side effects from Copaxone, but if I were to have had low lymphocytes from Tecfidera, was JCV+ (and in a dangerous risk group), I’d want to have the options of the old style drugs available.
We know that they are generally safe and well tolerated. OK, they only have an average relapse reduction rate of about 35%, but that’s better than Aubagio. And they are cheaper than Tysabri aren’t they? In fact they’re cheaper than Tecfidera, Aubagio and Tysabri.
What does everyone else think?